Intramolecularly lactam stapled oxyntomodulin analogues inhibit cancer cell proliferation in vitro

No abstract is available for this paper.

• Publication year

  2022

• Venue

  Chinese Chemical Letters

• Publication date

  2022-10-01

• Fields of study

  Not labeled

• Identifiers
  DOI 10.1016/j.cclet.2022.107920
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• A molecular link between diabetes and breast cancer: Therapeutic potential of repurposing incretin-based therapies for breast cancer.

  2021cited by this paper
• The current significance and prospects for the use of dual receptor agonism GLP-1/Glucagon.

  2021cited by this paper
• Dual-agonist incretin peptides from fish with potential for obesity-related Type 2 diabetes therapy - a review.

  2021cited by this paper
• Bicyclic stapled peptides based on p53 as dual inhibitors for the interactions of p53 with MDM2 and MDMX

  2021cited by this paper
• Design and characterization of novel oxyntomodulin derivatives with potent dual GLP-1/glucagon receptor activation and prolonged antidiabetic effects.

  2020cited by this paper
• New Generation Oxyntomodulin Peptides with Improved Pharmacokinetic Profiles Exhibit Weight Reducing and Anti-Steatotic Properties in Mice.

  2020cited by this paper
• A novel long-acting oxyntomodulin analogue eliminates diabetes and obesity in mice.

  2020cited by this paper
• Conjugation of a peptide to an antibody engineered with free cysteines dramatically improves half-life and activity

  2020cited by this paper
• Cotadutide. Dual glucagon-like peptide 1 receptor (GLP-1R)/glucagon receptor (GCGR) agonist, Treatment of diabetes, Treatment of nonalcoholic steatohepatitis, Treatment of obesity

  2020cited by this paper
• A novel dual glucagon‐like peptide and glucagon receptor agonist SAR425899: Results of randomized, placebo‐controlled first‐in‐human and first‐in‐patient trials

  2018cited by this paper
• Highly efficient detection of insulinotropic action of glucagon via GLP-1 receptor in mice pancreatic beta-cell with a novel perfusion microchip

  2016cited by this paper
• Design of Potent and Proteolytically Stable Oxyntomodulin Analogs.

  2016cited by this paper
• The double trouble of metabolic diseases: the diabetes–cancer link

  2015cited by this paper
• Glucagon-Like Peptide 1/Glucagon Receptor Dual Agonism Reverses Obesity in Mice

  2009cited by this paper
• A new glucagon and GLP-1 co-agonist eliminates obesity in rodents.

  2009cited by this paper

• Study of Serum Gremlin-1, Galectin-3, and Oxyntomodulin in Women with Breast Cancer

  2024cites this paper